Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1976 Apr;3(2):251–257. doi: 10.1111/j.1365-2125.1976.tb00600.x

beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers.

W H Aellig
PMCID: PMC1428873  PMID: 973959

Abstract

The beta-adrenoceptor blocking activities of pindolol and propranolol have been investigated in healthy male volunteers. Pindolol was about forty times more potent than propranolol in reducing isoprenaline-induced tachycardia. Pindolol (5 mg) and propranolol (u99 mg) were approximately equiactive in reducing exercise-induced tachycardia, 2 h after oral administration. The duration of action of pindolol is significantly longer than that of propranolol; 24 h after pindolol (kmg), 36+/-5% of the masimum effect were still present, and after propranolol (100 mg) 16+/-4% remained. Despite the long duration of action of pindolol, there was no evidence for cumulation during oral administration of 5 mg t.d.s. for 5 days.

Full text

PDF
256

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aellig W. H. Isoprenaline antagonism and duration of action in exercise induced tachycardia of three -adrenoceptor blocking drugs: pindolol, LF 17-895 and propranolol. Br J Pharmacol. 1973 Mar;47(3):621P–622P. [PMC free article] [PubMed] [Google Scholar]
  2. Aellig W. H., Saameli K. Prolonged action of pindolol. Br Med J. 1973 May 12;2(5862):365–365. doi: 10.1136/bmj.2.5862.365-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gugler R., Herold W., Dengler H. J. Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol. 1974;7(1):17–24. doi: 10.1007/BF00614385. [DOI] [PubMed] [Google Scholar]
  4. Gugler R., Höbel W., Bodem G., Dengler H. J. The effect of pindolol on exercise-induced cardiac acceleration in relation to plasma levels in man. Clin Pharmacol Ther. 1975 Feb;17(2):127–133. doi: 10.1002/cpt1975172127. [DOI] [PubMed] [Google Scholar]
  5. Hill R. C., Turner P. Preliminary investigations of a new beta-adrenoceptive receptor blocking drug, LB46, in man. Br J Pharmacol. 1969 Jun;36(2):368–372. doi: 10.1111/j.1476-5381.1969.tb09511.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Prichard B. N., Aellig W. H., Richardson G. A. The action of intravenous oxprenolol, practolol, propranolol and sotalol on acute exercise tolerance in angina pectoris: the effect on heart rate and the electrocardiogram. Postgrad Med J. 1970 Nov;(Suppl):77–85. [PubMed] [Google Scholar]
  7. Prichard B. N. Beta-adrenergic receptor blocking drugs in angina pectoris. Drugs. 1974;7(1):55–84. doi: 10.2165/00003495-197407010-00005. [DOI] [PubMed] [Google Scholar]
  8. Shand D. G., Nuckolls E. M., Oates J. A. Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):112–120. doi: 10.1002/cpt1970111112. [DOI] [PubMed] [Google Scholar]
  9. Waal-Manning H. J., Wood A. J. Pindolol in hypertension: twice-daily versus thrice-daily dosage. Med J Aust. 1975 Aug 16;2(7):274–275. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES